Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 49Gynecologic 26Dermatologic 11Head & Neck 7Gastrointestinal 6Lymphoid 3Tumor-Agnostic 2Other hematologic neoplasm 2Genitourinary 2Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 164Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sentinel Lymph Node Biopsy × Other hematologic neoplasm × Clear all
NCT01649791 2016-06-30

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Roswell Park Cancer Institute

Phase NA Terminated
8 enrolled 9 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00621452 2014-08-06

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡